Ercalcitriol

Ercalcitriol

SCHEMBL301083

C=C1C(=CC=C2CCC[C@@]3(C)C2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)(C)O)C[C@@H](O)CC1O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 12/20 0.80
ADORA3 P0DMS8 3/20 0.78
SLC6A2 P23975 3/20 0.78
NR1I2 O75469 2/20 0.78
PGR P06401 2/20 0.78
SLC6A4 P31645 2/20 0.78
ADRA1A P35348 2/20 0.78
PTGS2 P35354 2/20 0.78
HTR1A P08908 1/20 0.78
MAPT P10636 2/20 0.71
AGTR1 P30556 2/20 0.71
ABCB11 O95342 1/20 0.71
GC P02774 1/20 0.71
RXRA P19793 1/20 0.71
CHRM3 P20309 1/20 0.71
CNR1 P21554 1/20 0.71
HTR2C P28335 1/20 0.71
MAPK1 P28482 1/20 0.71
OPRD1 P41143 1/20 0.71
OPRK1 P41145 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ercalcitriol SCHEMBL12922723 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL17274136 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL4393978 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL264876 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL264875 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL4398182 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL23142603 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL8776000 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL9050396 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR
Ercalcitriol SCHEMBL21433255 1.00 VDR (0.80) VDRADORA3SLC6A2NR1I2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3225243-B1 METHOD OF SAFELY AND EFFECTIVELY TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE OPKO RENAL LLC (US) 2025-09-03 EP claimed
US-11926583-B2 Stabilized 1, 25-dihydroxyvitamin D2 and method of making same EIRGEN PHARMA LTD. (IE) 2024-03-12 US claimed
US-11801275-B2 Compositions and methods for common colds M. ALPHABET 3, LLC (US) 2023-10-31 US claimed
US-11752158-B2 Method of treating vitamin D insufficiency and deficiency EIRGEN PHARMA LTD. (IE) 2023-09-12 US claimed
CN-113311080-B Joint detection method for multiple vitamin D metabolites, detection kit and application thereof 中国医学科学院北京协和医院 2023-02-21 CN claimed
CN-113631272-B Compositions, devices and methods for mitigating lipoprotein interference in vitro diagnostic assays for hydrophobic analytes 美国西门子医学诊断股份有限公司 2022-12-20 CN claimed
US-11452734-B2 Method of treating and preventing secondary hyperparathyroidism EIRGEN PHARMA LTD. (IE) 2022-09-27 US claimed
US-20210088486-A1 METHODS AND SYSTEMS FOR DETECTION OF VITAMIN D METABOLITES DH TECHNOLOGIES DEV PTE LTD (SG) 2021-03-25 US claimed
CN-111936851-A Methods and systems for detecting vitamin D metabolites DH科技发展私人贸易有限公司 2020-11-13 CN claimed
US-20200253987-A1 Method of Treating and Preventing Secondary Hyperparathyroidism EIRGEN PHARMA LTD. (IE) 2020-08-13 US claimed
US-20030022873-A1 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis DELUCA HECTOR F (US) 2003-01-30 US claimed
EP-1233942-A2 TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 2002-08-28 EP claimed
US-20020016313-A1 DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS WISCONSIN ALUMNI RESEARCH FOUNDATION 2002-02-07 US claimed
WO-2001042205-A2 TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 2001-06-14 WO claimed
EP-0587751-A1 THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION THE PROCTER & GAMBLE COMPANY (US) 1994-03-23 EP claimed
EP-0112332-B1 VITAMIN D GLYCOSIDES THE GENERAL HOSPITAL CORPORATION (US) 1993-06-16 EP claimed
WO-1992021365-A1 THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION THE PROCTER & GAMBLE COMPANY (US) 1992-12-10 WO claimed
EP-0042673-B1 CYTORECEPTOR ASSAY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1986-03-26 EP claimed
WO-1982000059-A1 CYTORECEPTOR ASSAY UNIV CALIFORNIA (US) 1982-01-07 WO claimed
EP-0042673-A1 Cytoreceptor assay THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1981-12-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016313-A1 DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS VDR, ORAI1, CYP24A1 VDR 1/4885ADORA3 605/4885SLC6A2 4127/4885
US-20030022873-A1 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis VDR, ORAI1, CYP24A1 VDR 1/4885ADORA3 605/4885SLC6A2 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.